Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of
cancer and abnormal cells and helps stop the patient's immune system from rejecting the
donor's stem cells. When the healthy stem cells from a donor are infused into the patient
they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,
and platelets. Sometimes the transplanted cells from a donor can make an immune response
against the body's normal cells. Giving cyclophosphamide, mycophenolate mofetil, or
tacrolimus after transplant may stop this from happening.
PURPOSE: This clinical trial is studying how well giving combination chemotherapy together
with tacrolimus and mycophenolate mofetil works in treating patients who are undergoing a
donor bone marrow transplant for hematologic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins